Head to Head Contrast: BioHarvest Sciences (NASDAQ:BHST) vs. Alterity Therapeutics (NASDAQ:ATHE)

BioHarvest Sciences (NASDAQ:BHST) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioHarvest Sciences and Alterity Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1	0	3	0	2.50
Alterity Therapeutics	1	1	1	0	2.00

BioHarvest Sciences presently has a consensus target price of $13.67, indicating a potential upside of 18.74%. Alterity Therapeutics has a consensus target price of $12.00, indicating a potential upside of 164.32%. Given Alterity Therapeutics’ higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than BioHarvest Sciences.

Valuation & Earnings

This table compares BioHarvest Sciences and Alterity Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$25.19 million	7.50	-$12.91 million	($0.70)	-16.44
Alterity Therapeutics	N/A	N/A	-$7.87 million	N/A	N/A

Alterity Therapeutics has lower revenue, but higher earnings than BioHarvest Sciences.

Volatility & Risk

BioHarvest Sciences has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Insider & Institutional Ownership

2.1% of Alterity Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares BioHarvest Sciences and Alterity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-39.95%	-11,357.84%	-39.94%
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats BioHarvest Sciences on 7 of the 11 factors compared between the two stocks.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.